We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| -36.00 | -0.34% | 10,424.00 | 10,424.00 | 10,428.00 |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 10,482.00 | 10,414.00 | 10,450.00 | 183,251 | 14:25:22 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8411 | 27.22 | 162.16B |
| Date | Time | Source | Headline |
|---|---|---|---|
| 24/12/2024 | 08:20 | ALNC |  AstraZeneca and Daiichi withdraw EU application for lung cancer drug |
| 24/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Dato-DXd NSQ NSCLC application withdrawn in EU |
| 23/12/2024 | 10:13 | ALNC | AstraZeneca receives EU approval for Tagrisso lung cancer treatment |
| 23/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Tagrisso approved in EU based on LAURA trial |
| 18/12/2024 | 12:44 | ALNC | PRESS: AstraZeneca sees sales slump in China after arrest of exec - FT |
| 16/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Directorate Change |
| 11/12/2024 | 19:40 | ALNC | IN BRIEF: Merck and AstraZeneca unveil long-term Lynparza results |
| 09/12/2024 | 09:09 | ALNC | AstraZeneca, Daiichi Sankyo hail US breakthrough therapy designation |
| 05/12/2024 | 09:46 | ALNC | AstraZeneca touts US FDA approval for small cell lung cancer treatment |
| 05/12/2024 | 07:00 | UK RNS | AstraZeneca PLC Imfinzi approved in US for limited-stage SCLC |
1 Year Astrazeneca Chart |
Intraday Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
